Most people now agree that it is possible to obtain a high degree of protection against Rh immunization by giving anti-D gammaglobulin intramuscularly to a non-immunized Rh-negative woman who has just been delivered of an Rhpositive ABO compatible baby. There remain a number of interesting points about the prophylaxis and it is with five of these that this paper is concerned.
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(1) Does it really work? Are fewer women becoming immunized and are fewer exchange transfusions necessary than before the treatment was introduced? At one Liverpool maternity hospital, Mill Road Hospital, the answer is 'yes' (B M Hibbard 1971, personal communication) . Since 1966 the immunization rate has decreased from an incidence of about 17 per 1000 hospital deliveries to 7 in 1970. The rate of decrease corresponds well with the increasing number of Rh-negative mothers who have become eligible for the treatment as anti-D has become more readily a-vailable. The exchange transfusion rate has also decreased by about 50% in the same period of time. Results from other centres in the UK and from other countries are awaited with interest.
(2) What are the reasons for the smallfailure rate? About 0.5% of women become immunized by six months after delivery and another 0.5% by the end of the next Rh-positive pregnancy in spite of having been given anti-D. This compares with 17 % by the end of the next Rh-positive pregnancy if nothing is done. The main reason for the failure rate is thought to be that the woman has been previously 'primed', that is, immunized, but that antibodies are not detectable by routine methods, though they can be by red cell survival studies. 'Priming' may have occurred during the pregnancy in question, or may have been caused by a previous abortion or a previous incompatible blood transfusion. Whichever the case, the anti-D is being given too late.
Some idea of the frequency with which 'priming' occurs should be obtainable by comparing the fcetal cell scores after delivery in Rh-negative women who have been delivered of an Rhpositive baby, with those whose baby was Rh-negative. Previous 'priming' would be expected to cause lower foetal cell scores, but the differences are likely to be small and very large numbers would be necessary. In small series which have been studied there is modest support for the hypothesis (J0rgensen & Freiesleben 1971, Davey 1971, Liverpool team, unpublished) .
(3) When is an antibody not an antibody? The problem here is to know whether an antibody detectable by enzyme techniques three months after delivery is the beginning of active immunization or the remains of the passively injected anti-D. The only certain way is by assessing;the situation at the end of the next Rh-positive pregnancy, but results in Liverpool and elsewhere show that nearly all doubtful cases turn out to be due to the remains of the injected anti-D.
(4) Why do not more women get immunized during pregnancy? It has been suggested that there may be a state of relative maternal anergy during pregnancy, such that the woman is much less likely to make humoral antibodies than when she is not pregnant. However, animal experiments suggest that this is not so (Woodrow, Elson & Donohoe 1971) , and the probable answer is that the effective transplacental himorrhage usually takes place towards the end of pregnancy, and that since Rh is a 'slow 'antigen the woman only makes Rh-antibodies later on.
(5) Is the anti-D specific for the D antigen, or does it protect against other red cell antigens? Most animal work strongly suggests specificity, but man may be different and an experiment is in progress in Liverpool to see if this is so. Groups of Rhnegative, Kell-negative male volunteers are being injected with 51Cr-labelled Rh-positive, Kellpositive red cells. Half the men are kept as controls and the other half are given anti-Kell antibody. The aim is to discover whether the anti-Kell protects, not only against the Kell, but also against the D antigen. (The investigation is done this way round because anti-D is more readily formed than anti-Kell.) To date two men, both controls, have developed anti-D; the results, therefore, perhaps whisper in favour of nonspecificity, but the matter is nowhere near proven. The genetic disorders of hemoglobin fall into two groups. There are the structural variants which result from single amino acid substitutions or deletions in either the a-or f-chains. In addition there are the thalassamias which result from a reduced rate of synthesis of one or more of the globin chains. This causes unbalanced chain production which results in ineffective erythropoiesis and shortened red cell survival.
There are few structural haemoglobinopathies which cause disease during the first few months of life. The y-chain mutants which have been reported to date have not been associated with any hmmatological changes. The clinically important ,8-chain variants like hlemoglobins S and C only cause symptoms after the third month when ,B-chain synthesis is fully established.
Of the a-chain variants which cause disease in adults, only the various forms of hemoglobin Ma have been observed in the neonatal period; they are associated with congenital cyanosis from birth.
It is likely that some of the high oxygen affinity variants such as hemoglobin Chesapeake cause neonatal polycythemia although this phenomenon has yet to be reported. Haemoglobin Constant Spring (CS) is an a-chain variant with 31 residues attached to the C-terminal end, which causes a reduced rate of a-chain synthesis (Milner et al. 1971 ). In the neonatal period this would probably result in an increased production of himoglobin Barts due to an overall deficit of a-chains; the hbmoglobin with a molecular formula a2Csy2 would probably not be observed.
This variant is widespread throughout South-east Asia and is the commonest a-chain variant yet described.
The a-thalasswmias cause a variety of clinical pictures in the neonatal period. The homozygous state for a-thalassmmia 1, or the severe form of a-thalassemia, produces hydrops foetalis and is a very frequent cause of this condition in South-east Asia.
Other combinations of the a-thalassmmia genes produce various hamatological changes in the neonatal period. The combination of the a-thalasswmia 1 and a-thalassaemia 2 genes causes a moderate degree of anemia and a thalassmmic blood picture. These infants have about 20% hemoglobin Barts and in adult life develop himoglobin H disease (Wasi et al. 1969 ). The a-thalassemia 1 and a-thalassamia 2 carrier states are associated with mild morphological abnormalities of the red cells and increased levels of hwemoglobin Barts.
Gamma-thalassmmia has yet to be fully documented but a disorder which probably results from defective y-and fl-chain production, yflthalassmmia, has recently been reported to cause a neonatal h2molytic disease (Kan et al. 1972 ).
